Advocacy article
Malaria Box article
Pathogen Box article
Scientific article

ACS Medicinal Chemistry Letters
Antimicrobial Agents and Chemotherapy
Book - Lead Generation: Methods, Strategies, and Case Studies
Current Topics in Medicinal Chemistry
Drug Design, Development and Therapy
Future Medicinal Chemistry
Journal of Medicinal Chemistry
Journal of Vector Borne Diseases
Malaria Journal
MedChemComm
Nature
Nature Communications
Nature Reviews Disease Primers
Nature Reviews Drug Discovery
PLOS Medicine
PLOS Neglected Tropical Diseases
PLOS ONE
Parasites & Vectors
Pathogens and Global Health
RSC Drug Discovery
Science
Science Translational Medicine
Scientific Reports
Trends in Parasitology

Abena Poku-Awuku
Adam Aspinall
Andrea Lucard
André-Marie Tchouatieu
Anne Claire Marrast
Belen Tornesi
Benoit Laleu
Brice Campo
Cristina Donini
Céline Audibert
Danielle Sessa
David Reddy
Delphine Baud
Didier Leroy
Doreen Yomoah
Elizabeth Poll
Elodie Jambert
Empty (11500)
Empty (12273)
Empty (12377)
Empty (12475)
Empty (12500)
Empty (13668)
Empty (9261)
Empty (9275)
Empty (9293)
Empty (9340)
George Jagoe
Hans Rietveld
Hanu Ramachandruni
Helen Demarest
Isabelle Borghini-Fuhrer
James Duffy
Jeremy Burrows
Jörg Möhrle
Maud Majeres Lugand
Myriam El Gaaloul
Mélanie Rouillier
Nada Abla Geiser
Nada Araeipour
Nathalie Gobeau
Paul Willis
Pierre Hugo
Silvia Ferazzi
Stephan Duparc
Stephan Chalon
Stephen Brand
Sylvie Fonteilles-Drabek
Tim Wells
Wiweka Kaszubska
Zaira Rizopoulos

Search form

Publications

Optimized pyridazinone nutrient channel inhibitors are potent and specific antimalarial leads

Volunteer infection studies accelerate the clinical development of novel drugs against malaria

Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials

MalDA, Accelerating Malaria Drug Discovery

Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series

Actives from MMV Open Access Boxes? A suggested way forward

MAIP: a web service for predicting blood-stage malaria inhibitors

Targeting Plasmepsins-An Achilles' Heel of the Malaria Parasite

An in vitro toolbox to accelerate anti-malarial drug discovery and development

Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study

The Development Process for Discovery and Clinical Advancement of Modern Antimalarials

Blocking Plasmodium Development in Mosquitoes: A Powerful New Approach for Expanding Malaria Control Efforts.

Cyclization-blocked proguanil as a strategy to improve the antimalarial activity of atovaquone

Partnering to fight malaria in India: Past, present and future

A discovery and development roadmap for new endectocidal transmission-blocking agents in malaria

Open-source discovery of chemical leads for next-generation chemoprotective antimalarials

Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome

Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria

Evaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in Vitro

Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγnull Mouse Model of Malaria

Modelling mosquito infection at natural parasite densities identifies drugs targeting

The Discovery of Novel Antimalarial Aminoxadiazoles as a Promising Nonendoperoxide Scaffold

Malaria

Assessing the anthelmintic activity of pyrazole-5-carboxamide derivatives against Haemonchus contortus

Parasite physiology: No longer lost in translation

Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase

Shared Consensus Machine Learning Models for Predicting Blood Stage Malaria Inhibition

Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model

Arylmethylamino steroids as antiparasitic agents

New developments in anti-malarial target candidate and product profiles

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy Modeling

Open data in drug discovery and development: lessons from malaria

Lead Structure Discovery for Neglected Diseases: Product Development Partnerships Driving Drug Discovery

Tetrahydro-2-naphthyl and 2‑Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity

A Proposed Target Product Profile and Developmental Cascade for New Cryptosporidiosis Treatments

Hit and lead criteria in drug discovery for infectious diseases of the developing world

A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria

Killing the hypnozoite – drug discovery approaches to prevent relapse in Plasmodium vivax

Malaria runs rings round artemisinin

Subtle changes in endochin-like quinolone (ELQ) structure alter site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum

Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum

Defining the biology component of the drug discovery strategy for malaria eradication

Screening and hit evaluation of a chemical library against blood-stage Plasmodium falciparum

Fluorine Modulates Species Selectivity in the Triazolopyrimidine Class of Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors

The role of modern drug discovery in the fight against neglected and tropical diseases

Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers

In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models

Advancing antimalarial drug research through open source initiatives

The Open Access Malaria Box: A Drug Discovery Catalyst for Neglected Diseases

The Open Access Malaria Box: A Drug Discovery Catalyst for Neglected Diseases

Designing the next generation of medicines for malaria control and eradication

Quinolone-3-Diarylethers: A New Class of Antimalarial Drug

Antimalarial drug discovery: where next?

The Malaria Box: a catalyst for drug discovery

The global pipeline of new medicines for the control and elimination of malaria

Identification and In-Vitro ADME Assessment of a Series of Novel Anti-Malarial Agents Suitable for Hit-to-Lead Chemistry

A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold

Neglected Diseases and Drug Discovery

Cyclopropyl carboxamides, a chemically novel class of antimalarial agents identified in a phenotypic screen

Novel Orally Active Antimalarial Thiazoles

Pages